Abstract
The humanized monoclonal anti-IgE antibody omalizumab is currently the only biologic drug approved for asthma treatment. Omalizumab inhibits allergic responses by binding to serum immunoglobulins E (IgE), thus preventing their interactions with cellular IgE receptors. Omalizumab is also capable of down-regulating the expression of high affinity IgE receptors on inflammatory cells, as well as the numbers of eosinophils in both peripheral blood and induced sputum. The clinical effects of omalizumab include relevant improvements in respiratory symptoms and quality of life, paralleled by a marked reduction of asthma exacerbations, emergency room visits, and use of systemic corticosteroids and rescue bronchodilators. Moreover, some recent studies suggest potential benefits of omalizumab also in non allergic phenotypes of severe asthma. Very interesting are also further recent reports referring to the potential inhibitory effect of omalizumab with regard to bronchial structural changes, especially occurring in severe asthma and globally defined as airway remodeling. Omalizumab is relatively well tolerated, and only very rarely induces anaphylactic reactions. Therefore, this drug represents a valid option as add-on therapy for patients with severe persistent asthma, inadequately controlled by high doses of standard inhaled treatments.
Keywords: Anti-IgE, omalizumab, severe asthma.
Current Drug Targets
Title:Anti-IgE Therapy with Omalizumab for Severe Asthma: Current Concepts and Potential Developments
Volume: 16 Issue: 2
Author(s): Girolamo Pelaia, Alessandro Vatrella, Maria Teresa Busceti, Luca Gallelli, Rosa Terracciano and Rosario Maselli
Affiliation:
Keywords: Anti-IgE, omalizumab, severe asthma.
Abstract: The humanized monoclonal anti-IgE antibody omalizumab is currently the only biologic drug approved for asthma treatment. Omalizumab inhibits allergic responses by binding to serum immunoglobulins E (IgE), thus preventing their interactions with cellular IgE receptors. Omalizumab is also capable of down-regulating the expression of high affinity IgE receptors on inflammatory cells, as well as the numbers of eosinophils in both peripheral blood and induced sputum. The clinical effects of omalizumab include relevant improvements in respiratory symptoms and quality of life, paralleled by a marked reduction of asthma exacerbations, emergency room visits, and use of systemic corticosteroids and rescue bronchodilators. Moreover, some recent studies suggest potential benefits of omalizumab also in non allergic phenotypes of severe asthma. Very interesting are also further recent reports referring to the potential inhibitory effect of omalizumab with regard to bronchial structural changes, especially occurring in severe asthma and globally defined as airway remodeling. Omalizumab is relatively well tolerated, and only very rarely induces anaphylactic reactions. Therefore, this drug represents a valid option as add-on therapy for patients with severe persistent asthma, inadequately controlled by high doses of standard inhaled treatments.
Export Options
About this article
Cite this article as:
Pelaia Girolamo, Vatrella Alessandro, Teresa Busceti Maria, Gallelli Luca, Terracciano Rosa and Maselli Rosario, Anti-IgE Therapy with Omalizumab for Severe Asthma: Current Concepts and Potential Developments, Current Drug Targets 2015; 16 (2) . https://dx.doi.org/10.2174/1389450116666141219122157
DOI https://dx.doi.org/10.2174/1389450116666141219122157 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Withdrawal Notice: ModStore: Genotype Imputation as a Service Powered by SG10K Reference Panel
Current Bioinformatics The Role of Minocycline in Ischemia-Reperfusion Injury: A Comprehensive Review of an Old Drug with New Implications
Recent Patents on Cardiovascular Drug Discovery Current Concepts for Optimizing the Therapeutic Index of Glucocorticoid Receptor Ligands for Oral and Inhalative Use: Basic Considerations and Clinical Reality
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Celastrol Inhibits Inflammatory Stimuli-Induced Neutrophil Extracellular Trap Formation
Current Molecular Medicine Alpha-1 Antitrypsin Deficiency and Chronic Obstructive Pulmonary Disease: Between Overlaps, Phenotypes and Illnesses
Current Respiratory Medicine Reviews Herbal Medicines for Diabetes Management and its Secondary Complications
Current Diabetes Reviews Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment
Current Neuropharmacology Current Animal Models of Bronchial Asthma
Current Pharmaceutical Design In Vitro Evaluation of Antimicrobial and Antiproliferative Activities for Compounds Isolated from the Ficus Bubu Warb. (Moraceae) Fruits: Chemotaxonomic Significance
Drug Delivery Letters Long Noncoding RNA GAS5: A Novel Marker Involved in Glucocorticoid Response
Current Molecular Medicine Dual Acting Anti-Inflammatory Drugs
Current Topics in Medicinal Chemistry Progress and Prospects of Polyplex Nanomicelles for Plasmid DNA Delivery
Current Gene Therapy Electronic Monitoring of Adherence to Inhaled Medication in Asthma
Current Respiratory Medicine Reviews Sleep Related Disorders in the Elderly: An Overview
Current Respiratory Medicine Reviews Recent Updates on Biological Activities of Oxadiazoles
Mini-Reviews in Medicinal Chemistry Pharmacogenomics in the Americas: The Impact of Genetic Admixture
Current Drug Targets Anti Citrullinated Protein Antibodies and Mechanism of Action of Common Disease Modifying Drugs - Insights in Pathomechanisms of Autoimmunity
Current Pharmaceutical Design Paracetamol-Induced Stevens Johnson Syndrome and Cholestatic Hepatitis
Current Drug Safety Relaxin Receptors - New Drug Targets for Multiple Disease States
Current Drug Targets Patent Selections:
Recent Patents on Inflammation & Allergy Drug Discovery